Relationship of plasma homocysteine, soluble intercellular adhesion molecule-1, high mobility group box 1 protein with carotid intima-media thickness in elderly patients with type 2 diabetes mellitus

Objective:To explore the relationship of plasma homocysteine(Hcy),soluble intercellular adhesion molecule-1(sICAM-1)and high mobility group box 1 protein(HMGB1)with carotid intima-media thickness(c-IMT)in elderly patients with type 2 diabetes mellitus.Methods:A total of 100 elderly patients who were diagnosed as type 2 diabetes mellitus in Baogang Hospital of Inner Mongolia from June 2017 to May 2020 were chosen as research objects.According to c-IMT,they were divided into the normal group(n=35),the mild to moderate group(n=41)and the severe group(n=24).The expression levels of plasma Hcy,sICAM-1 and HMGB1 were compared between groups respectively.Pearson’s correlation coefficient was used to analyze the relationship of plasma Hcy,sICAM-1,HMGB1 with c-IMT.Results:The comparison in plasma Hcy,sICAM-1,HMGB1 and c-IMT among the three groups of patients was of statistical significance(p<.05).The results of correlation analysis showed that the expression levels of plasma Hcy,sICAM-1 and HMGB1 were positively correlated with c-IMT in elderly patients with type 2 diabetes mellitus(r=.627,.598,.614;p<.05).Conclusions:The expression levels of plasma Hcy,sICAM-1 and HMGB1 are abnormally increased in elderly patients with type 2 diabetes mellitus,and related to c-IMT,which can provide a strong evidence for clinical diagnosis and treatment by detecting their levels in clinical practice.

Concurrent silencing of TBCE and drug delivery to overcome platinum-based resistance in liver cancer

Platinum-based chemotherapy resistance is a key factor of poor prognosis and recurrence in hepatocellular carcinoma(HCC).Herein,RNAseq analysis revealed that elevated tubulin folding cofactor E(TBCE)expression is associated with platinum-based chemotherapy resistance.High expression of TBCE contributes to worse prognoses and earlier recurrence among liver cancer patients.Mechanistically,TBCE silencing significantly affects cytoskeleton rearrangement,which in turn increases cisplatin-induced cycle arrest and apoptosis.To develop these findings into potential therapeutic drugs,endosomal pH-responsive nanoparticles(NPs)were developed to simultaneously encapsulate TBCE siRNA and cisplatin(DDP)to reverse this phenomena.NPs(siTBCE+DDP)concurrently silenced TBCE expression,increased cell sensitivity to platinum treatment,and subsequently resulted in superior anti-tumor effects both in vitro and in vivo in orthotopic and patient-derived xenograft(PDX)models.Taken together,NP-mediated delivery and the co-treatment of siTBCE+DDP proved to be effective in reversing chemotherapy resistance of DDP in multiple tumor models.

Nanoparticles(NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy

Monoclonal antibody-based therapy has achieved great success and is now one of the most crucial therapeutic modalities for cancer therapy.The first monoclonal antibody authorized for treating human epidermal growth receptor 2(HER2)-positive breast cancer is trastuzumab.However,resistance to trastuzumab therapy is frequently encountered and thus significantly restricts the therapeutic outcomes.To address this issue,tumor microenvironment(TME)pH-responsive nanoparticles(NPs)were herein developed for systemic mRNA delivery to reverse the trastuzumab resistance of breast cancer(BCa).This nanoplatform is comprised of a methoxyl-poly(ethylene glycol)-b-poly(lactic-co-glycolic acid)copolymer with a TME pH-liable linker(Meo-PEG-Dlinkm-PLGA)and an amphiphilic cationic lipid that can complex PTEN mRNA via electrostatic interaction.When the long-circulating mRNA-loaded NPs build up in the tumor after being delivered intravenously,they could be efficiently internalized by tumor cells due to the TME pH-triggered PEG detachment from the NP surface.With the intracellular mRNA release to up-regulate PTEN expression,the constantly activated PI3K/Akt signaling pathway could be blocked in the trastuzumab-resistant BCa cells,thereby resulting in the reversal of trastuzumab resistance and effectively suppress the development of BCa.

Long-term outcomes following exclusive use of endovascular aortic repair for ruptured infrarenal abdominal aortic aneurysms

To the Editor:Ruptured abdominal aortic aneurysm(rAAA)is a fatal disease.Emergency surgery is the only way to provide an opportunity for survival.In 1994,endovascular aortic repair(EVAR)was reported as an emergency treatment for rAAA.Compared with traditional open surgery(OS),patients could benefit from its lower perioperative mortality and minimal invasiveness.Although recent guidelines have recommended an EVARfirst approach if suitable as judged by the clinician,the standard of whether to give a priority to EVAR varies among clinicians in practical applications,because hostile aortic morphology and hemodynamic conditions were thought to weaken the benefit of EVAR.Hence,controversies still exist regarding whether EVAR as a priority is applicable to most rAAAs.In addition,a search of the literature found few population-based studies with long-term outcomes.Given this,a population-based study was conducted by Zhongshan Hospital,Fudan University.

A balloon-supported embolism protection technique during vertebral/ subclavian artery angioplasty stenting

With high rates of morbidity and mortality,posterior circulation stroke accounts for 20% of ischemic strokes,and approximately 25% occurs in patients with stenosis in the vertebral and/or basilar arteries.liiOn the other hand,the risk of posterior circulation ischemic stroke reaches 30% in patients with symptomatic vertebral artery(VA)stenosis afterSyears,[2]subclavian artery(SA)occlusion,although with a low prevalence in the general population,is also an important causeof posterior circulation stroke.